Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

Journal of Clinical Oncology

Volumn 20, Issue 3, 2002, Pages 719-726

  Vogel, Charles L ^a   Cobleigh, Melody A ^a   Tripathy, Debu ^a   Gutheil, John C ^a   Harris, Lyndsay N ^a   Fehrenbacher, Louis ^a   Slamon, Dennis J ^a   Murphy, Maureen ^a   Novotny, William F ^a   Burchmore, Michael ^a   Shak, Steven ^a   Stewart, Stanford J ^a   Press, Michael ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRASTUZUMAB;

ADULT; AGED; ARTICLE; ASTHENIA; BREAST CANCER; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; NAUSEA; ONCOGENE NEU; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MIDDLE AGED; QUALITY OF LIFE; SAFETY; TREATMENT OUTCOME;

EID: 0036467826     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.3.719     Document Type: Article

References (14)

1. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/ neu oncogene
2. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
3. The biology of erbB-2/neu/HER-2 and its role in cancer
4. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers - A review
5. Humanization of an anti-p 185HER2 antibody for human cancer therapy
6. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
7. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
8. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology
9. C-erbB-2 oncoprotein expression in primary and advanced breast cancer
10. ® pivotal trials
11. ® (trastuzumab) as a single agent in first-line treatment of HER2-overexpressing in Metastatic Breast Cancer (HER2+/MBC)
12. ® (trastuzumab, humanized anti-HER2 antibody)
13. Health related quality of life (HRQL) of patients treated with first-line, single agent, trastuzumab (Herceptin) for metastatic Her-2 overexpressing breast cancer (MBC)